Compare LAZ & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAZ | IDYA |
|---|---|---|
| Founded | 1848 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2004 | 2019 |
| Metric | LAZ | IDYA |
|---|---|---|
| Price | $38.45 | $31.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $43.00 | ★ $52.38 |
| AVG Volume (30 Days) | ★ 1.7M | 806.6K |
| Earning Date | 10-22-2026 | 11-10-2026 |
| Dividend Yield | ★ 5.06% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $3,186,466,000.00 | $218,710,000.00 |
| Revenue This Year | $6.00 | N/A |
| Revenue Next Year | $19.51 | $188.45 |
| P/E Ratio | $32.95 | ★ N/A |
| Revenue Growth | 1.48 | ★ 3024.43 |
| 52 Week Low | $34.13 | $26.81 |
| 52 Week High | $58.75 | $42.68 |
| Indicator | LAZ | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 34.28 |
| Support Level | $34.65 | $29.74 |
| Resistance Level | $45.71 | $31.95 |
| Average True Range (ATR) | 1.59 | 1.54 |
| MACD | 0.46 | -0.17 |
| Stochastic Oscillator | 68.76 | 3.66 |
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.